No change
Add to watchlist
Create an alert
Stocks and Shares ISA
Fund and Share AccountScopus BioPharma Inc. is a biopharmaceutical company. The Company is developing therapeutics targeting serious diseases with significant unmet medical needs. Its lead development programs are CO-sTiRNA and MRI-1867. Its CO-sTiRNA is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. CO-sTiRNA is a dual-action STAT3 inhibitor. STAT3 is a gene that drives tumor cell growth and anti-tumor immune suppression. CO-sTiRNA also stimulates TLR9 receptors to activate the body’s immune defense to recognize and kill cancer cells. It is also developing MRI-1867 for the treatment of SSc. SSc is a chronic, systemic autoimmune disease. MRI-1867, is a peripherally-restricted, dual-action cannabinoid-1, or CB1, receptor inverse agonist and inhibitor of inducible nitric oxide synthase, or iNOS.
Company Information
About this company
Key people
Joshua R. Lamstein
Chairman of the Board, Principal Executive Officer
Robert J. Gibson
Vice Chairman of the Board, Treasurer, Secretary
Alan M. Horsager
President - Immuno-Oncology and President and Chief Executive Officer of Duet BioTherapeutics
Aharon Schwartz
Executive Chairman of Scopus BioPharma Israel Ltd
Ira Scott Greenspan
Director
David A. Buckel
Independent Director
Raphael Hofstein
Independent Director
David Weild
Independent Director
Click to see more
Key facts
- Shares in issue42.08m
- EPICSCPS
- ISINUS8091711015
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$16,830.00
- Employees13
- ExchangeOver The Counter
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.